Laurence Radin, MD
Neurology · New London, CTNPI 1508860156
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 782 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,147 and has fallen 79.2% since, to $654 in 2025.
Across 782 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$1K
- Biogen$1K
- EMD Serono, Inc.$1K
- Amgen$795
- Neurocrine Biosciences, Inc.$678
- plus $9K from 54 others
Across 145 payments — averaging $2452.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Adamas Pharmaceuticals, Inc.$217K
- H. Lundbeck A S$49K
- Amgen$42K
- Avanir Pharmaceuticals, Inc.$24K
- Eli Lilly$16K
- Biohaven Pharmaceuticals, Inc.$7K
What the payments were for
- Speaking & faculty fees$2111%
- Food & beverage$14,53398%
- Education$700%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$14,814 in reported general payments places this provider in the 80th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 12 | $135,747 |
| Nurtec OdtRimegepant Sulfate | 33 | $59,001 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $57,044 |
| OxycontinOxycodone Hcl | 24 | $21,521 |
| NeuproRotigotine | 21 | $18,233 |
| Gabapentin | 488 | $17,743 |
| LamictalLamotrigine | 13 | $16,455 |
| UbrelvyUbrogepant | 15 | $15,790 |
| VimpatLacosamide | 12 | $13,009 |
| Emgality PenGalcanezumab-Gnlm | 12 | $10,177 |
| BotoxOnabotulinumtoxina | 12 | $9,089 |
| Levetiracetam | 295 | $8,277 |
| DilantinPhenytoin Sodium Extended | 17 | $6,788 |
| Carbamazepine ErCarbamazepine | 57 | $6,772 |
| Carbamazepine | 59 | $6,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt, Dilantin | $368 | $201,53562 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $15 | $57,04412 claims |
| UCB, Inc.Neupro, Vimpat | $661 | $31,24233 claims |
| AbbVieUbrelvy, Botox | $1,279 | $24,87927 claims |
| Upsher-smith Laboratories LLCTopiramate | $138 | $1,751108 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $160 | $1,06122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 280 neurology providers in Connecticut.
Other neurology in New London
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
- Duarte MachadoCheshire$426K
- Tanya BilchikEast Hartford$361K
- Peter GottschalkFairfield$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.